 |
|
Dysplastic Nevi as Risk Markers of Sporadic (Nonfamilial) MelanomaA Case-Control Study
Allan C. Halpern, MD;
DuPont Guerry IV, MD;
David E. Elder, MD;
Wallace H. Clark, Jr, MD;
Marie Synnestvedt, MS;
Sandra Norman, PhD;
Robert Ayerle, MD
Arch Dermatol. 1991;127(7):995-999.
Abstract
• The melanoma risk associated with dysplastic nevi outside the context of familial melanoma was studied by the case-control method. One hundred five newly diagnosed incident melanoma cases with negative family histories for familial melanoma and 181 controls (frequency matched for race, age, and sex) were studied by personal interview and cutaneous examination. The prevalence of dysplastic nevi was 41 (39%) of 105 in the cases and 13 (7%) of 181 in the controls. The odds ratio for dysplastic nevi by multiple logistic regression analysis simultaneously correcting for age, sex, eye color, hair color, actinic damage, freckles, and total number of nondysplastic nevi was 6.8 (95% confidence interval, 2.7,16.9). This study supports the significance of dysplastic nevi as markers of increased risk for nonfamilial melanoma.
(Arch Dermatol. 1991;127:995-999)
Author Affiliations
From the University of Pennsylvania Pigmented Lesion Study Group, and the Department of Dermatology (Drs Halpern and Clark and Ms Synnestvedt), the Clinical Epidemiology Unit, Section of General Internal Medicine (Drs Halpern and Norman), the Department of Pathology (Dr Elder), the Cancer Center and the Hematology/Oncology Section, and the Department of Medicine (Dr Guerry), University of Pennsylvania, Philadelphia; and the Medical Department, Scott Paper Company, Philadelphia, Pa (Dr Ayerle).
Footnotes
Accepted for publication March 11, 1991.
Reprint requests to Department of Dermatology, 3600 Spruce St, Philadelphia, PA 19104 (Dr Halpern).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Melanocyte-specific Immune Response in a Patient with Multiple Regressing Nevi and a History of Melanoma
SPEECKAERT et al.
Anticancer Res 2011;31:3697-3703.
ABSTRACT
| FULL TEXT
Neonatal Blue Light Phototherapy and Melanocytic Nevi: A Twin Study
Csoma et al.
Pediatrics 2011;128:e856-e864.
ABSTRACT
| FULL TEXT
Skin Cancer Screening by Dermatologists, Family Practitioners, and Internists: Barriers and Facilitating Factors
Oliveria et al.
Arch Dermatol 2011;147:39-44.
ABSTRACT
| FULL TEXT
Estimating the Attributable Fraction for Cancer: A Meta-analysis of Nevi and Melanoma
Olsen et al.
Cancer Prev Res 2010;3:233-245.
ABSTRACT
| FULL TEXT
A call for the development and implementation of a targeted national melanoma screening program.
Geller et al.
Arch Dermatol 2006;142:504-507.
FULL TEXT
Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues
Hussein
J. Clin. Pathol. 2005;58:453-456.
ABSTRACT
| FULL TEXT
Repair of UV Light-Induced DNA Damage and Risk of Cutaneous Malignant Melanoma
Wei et al.
JNCI J Natl Cancer Inst 2003;95:308-315.
ABSTRACT
| FULL TEXT
Melanoma Information on the Internet: Often Incomplete--A Public Health Opportunity?
Bichakjian et al.
JCO 2002;20:134-141.
ABSTRACT
| FULL TEXT
Nonpigmented Dysplastic Melanocytic Nevi
Knoell et al.
Arch Dermatol 1997;133:992-994.
ABSTRACT
Clinically Recognized Dysplastic Nevi: A Central Risk Factor for Cutaneous Melanoma
Tucker et al.
JAMA 1997;277:1439-1444.
ABSTRACT
Risk of Cutaneous Malignant Melanoma in Patients With 'Classic' Atypical-Mole Syndrome: A Case-Control Study
Marghoob et al.
Arch Dermatol 1994;130:993-998.
ABSTRACT
Dermatology
Dover and Arndt
JAMA 1992;268:342-344.
ABSTRACT
|
